Biocompatible 3D Printing Materials Market Trends Analysis Report 2025-2030: Increasing Demand of Biocompatible 3D Printing Materials in Healthcare Settings
Dublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "Biocompatible 3D Printing Materials Market Size, Share & Trends Analysis Report By Type, By Application, By Region, and Segment Forecasts, 2025 - 2030" report has been added to ResearchAndMarkets.com's offering.The global biocompatible 3D printing materials market size was estimated at USD 664.7 million in 2024 and is projected to grow at a CAGR of 14.6% from 2025 to 2030
Advancements in 3D printing techniques, including developing specialized biocompatible materials, enable the creation of patient-specific devices with enhanced functionality and improved integration with the human body. In April 2024, a study in Biomedicines assessed the safety and feasibility of biocompatible 3D printing materials for intra-procedural guides in cardiac ablation. Prototypes showed good geometrical integrity post-sterilization, but traces of nitrogen and sulfur were found in some samples after ablation, indicating a need for additional clinical research.
The healthcare industry is experiencing a rising demand for biocompatible materials used in medical applications such as implants, prosthetics, and tissue engineering. These materials are designed to be compatible with the human body, reducing the likelihood of rejection or negative reactions. This demand is driving the development of advanced biocompatible materials for 3D printing. In June 2024, BIO INX launched DEGRES INX, an innovative biodegradable resin with shape memory capabilities designed for DLP-based 3D-(bio)printing. This unique material can be deformed temporarily and returns to its original shape when heated to body temperature. Furthermore, it meets ISO biocompatibility standards, making it suitable for cell cultivation.Recent technological advancements in 3D printing have significantly influenced the market for biocompatible materials. Innovations in materials and printing processes have created safe and effective options for medical applications. In October 2024, VBN Components, a Swedish company, made significant advancements in wear-resistant additive manufacturing materials. Their Vibenite portfolio featured innovative alloys poised to replace cobalt chrome in medical implants due to increasing safety concerns associated with cobalt chrome usage.The rise of personalized medicine is further propelling the biocompatible 3D printing materials market. This approach focuses on providing customized treatments based on individual patient characteristics, such as genetic makeup and lifestyle choices. In the realm of 3D printing, personalized medicine facilitates the creation of tailored medical devices, implants, and pharmaceuticals specifically designed to address the unique needs of each patient.
In October 2024, Boston Micro Fabrication (BMF) introduced four new materials for its microArch series 3D printers, specifically targeting the medical device sector. The HTF resin stands out for its high-temperature resistance, biocompatibility, and flexibility, making it ideal for medical applications where sterilization and material performance are critical.Competitive Landscape of Key Players
Formlabs Inc.
3D Systems Inc.
Evonik Industries AG
Stratasys
Concept Laser Gmbh
Renishaw plc
ENVISIONTEC US LLC
CELLINK
DETAX Ettlingen
Hoganas AB
Key Attributes:
Report Attribute
Details
No. of Pages
110
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$664.7 million
Forecasted Market Value (USD) by 2030
$1480 million
Compound Annual Growth Rate
14.6%
Regions Covered
Global
Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary 2.1. Market Outlook2.2. Segment Outlook2.2.1. Type outlook2.2.2. Application outlook2.3. Competitive InsightsChapter 3. Biocompatible 3D Printing Materials Market Variables, Trends & Scope 3.1. Market Lineage Outlook3.1.1. Parent market outlook3.1.2. Related/ancillary market outlook3.2. Market Dynamics3.2.1. Market driver analysis3.2.1.1. Increasing demand of biocompatible 3D printing materials in healthcare industry3.2.1.2. Technological advancements in 3D printing materials3.2.1.3. Growing adoption of personalized medicine3.2.2. Market restraint analysis3.2.2.1. High cost of biocompatible 3D printing materials3.2.2.2. Regulatory hurdles3.3. Biocompatible 3D Printing Materials Market Analysis Tools3.3.1. Industry Analysis - Porter's3.3.2. PESTEL AnalysisChapter 4. Biocompatible 3D Printing Materials Market: Type Estimates & Trend Analysis 4.1. Global Biocompatible 3D Printing Materials Market: Type Dashboard4.2. Global Biocompatible 3D Printing Materials Market: Type Movement Analysis4.3. Global Biocompatible 3D Printing Materials Market by Type, Revenue4.4. Polymer4.4.1. Polymer market estimates and forecasts 2018 to 2030 (USD Billion)4.5. Metal4.6. OthersChapter 5. Biocompatible 3D Printing Materials Market: Application Estimates & Trend Analysis 5.1. Global Biocompatible 3D Printing Materials Market: Application Dashboard5.2. Global Biocompatible 3D Printing Materials Market: Application Movement Analysis5.3. Global Biocompatible 3D Printing Materials Market by Application, Revenue5.4. Implants & Prosthesis5.4.1. Implants & Prosthesis market estimates and forecasts 2018 to 2030 (USD Billion)5.5. Prototyping & Surgical Guides5.6. Tissue Engineering5.7. Hearing Aids5.8. OthersChapter 6. Biocompatible 3D Printing Materials Market: Regional Estimates & Trend Analysis by Country, Type, and Application 6.1. Regional Dashboard6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030Chapter 7. Competitive Landscape 7.1. Recent Developments & Impact Analysis, By Key Manufacturers7.2. Company/Competition Categorization7.3. Vendor Landscape7.3.1. List of key distributors and channel partners7.3.2. Key customers7.3.3. Key company market share analysis, 20247.4. Company Profiles7.4.1. Company overview7.4.2. Financial performance7.4.3. Product benchmarking7.4.4. Strategic initiatives
For more information about this report visit https://www.researchandmarkets.com/r/nkwbom
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Biocompatible 3D Printing Materials Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
17 minutes ago
- Business Upturn
IKS Health Reports Robust Q1 FY26 Results with 16% Year-over-Year Revenue Growth and 59% Year-over-Year PAT Increase
By Business Wire India Published on July 31, 2025, 23:11 IST Inventurus Knowledge Solutions Limited (NSE: IKS), a technology-enabled healthcare solutions provider, today announced strong growth in Q1 FY26. IKS Health, a care enablement platform focused on supporting physician enterprises primarily in the US, reported its financial results for the quarter ended June 30, 2025. Business Wire India Revenue growth in Q1 16% YoY in INR, 13% YoY in USD Q1 EBITDA up 36% YoY; 5% QoQ PAT up 59% YoY; 3% QoQ Inventurus Knowledge Solutions Limited (NSE: IKS), a technology-enabled healthcare solutions provider, today announced strong growth in Q1 FY26. IKS Health, a care enablement platform focused on supporting physician enterprises primarily in the US, reported its financial results for the quarter ended June 30, 2025. 'Our performance this quarter reflects the continued momentum in our business and the stickiness of our integrated tech-led care enablement platform built on strong client relationships, scalable solutions, and disciplined execution,' said Sachin K. Gupta, Founder & Global CEO, IKS Health. 'The sustained revenue growth at 16% and improvement of EBITDA margin for the combined entity to 32% demonstrates the impact of our technology-led care enablement platform and global delivery capabilities. As we move forward, our focus remains on deepening client value, investing in innovation, and scaling our platform to address the evolving needs of the healthcare ecosystem.' Nithya Balasubramanian, CFO, IKS Health, said, 'We delivered a strong financial performance in Q1 FY26, driven by consistent revenue growth and continued focus on operational efficiency. Our EBITDA margin improvement reflects disciplined cost management, scalability of our platform, and prudent capital allocation. As we move ahead, we remain committed to sustaining healthy margins while strategically investing in capabilities that drive long-term value creation.' Key Financial Highlights: Q1FY26 ended on June 30, 2025 Revenue at INR 7,401 million (15.6% YoY / + 2.2% QoQ growth) EBITDA at INR 2,378 million at 32.1% of revenue (36.3% YoY / +5.1% QoQ growth) PAT at INR 1,515 million at 20.5% of revenue (58.7% YoY / 2.5% QoQ growth) Adjusted PAT at INR1,682 million at 22.7% of revenue (51.4% YoY / 2.2% QoQ growth) Business Highlights: IKS Health continues to expand its reach and impact through strategic partnerships. The following highlights key collaborations, including both new alliances and the expansion of existing relationships, that demonstrate the company's commitment to driving financial outcomes, enabling growth, and enhancing clinical efficiencies for healthcare providers. Mission Community Hospital: New partnership to drive financial outcomes and accountability with end-to-end revenue cycle across the hospital acute care and ambulatory surgery spaces Bicycle Health: New partnership leveraging IKS to manage revenue cycle, enabling rapid growth and scale of the virtual network OrthoNY: Expanded partnership to introduce IKS Virtual Clinical Assistant at a growing specialty network to take on administrative tasks and support clinical efficiencies in addition to existing RCM services. A top 5 Health System: Expanded partnership for coding to drive revenue performance and mitigate operational inefficiencies. Recognition & Awards IKS Health received the below notable recognitions: ET HRWorld Exceptional Employee Experience – Large Scale Award BW CFO Finance & Strategy Excellence Awards Excellence in Mergers and Acquisitions Award – Gold (Organizational Category) Best Woman CFO, Nithya Balasubramanian (Individual Category) Safe Harbour Certain statements in this release concerning our future growth prospects may be seen as forward-looking statements, which involve a number of risks and uncertainties that could cause the actuals to differ materially from such statements. It is not possible to undertake to update any such statement that may have been made from time to time. Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
USA Today
42 minutes ago
- USA Today
Best Buy adding IKEA showrooms in some stores: See where
An IKEA inside a Best Buy? It's happening, sort of. The popular Swedish furniture store is teaming up with the electronics giant to bring kitchen and laundry planning to select Best Buy stores across the country. Beginning in the fall, customers shopping at 10 Best Buy stores will be able to get "inspiration, planning support and make purchases for their kitchens and laundry rooms like never before," according to the retailer's news release. The partnership, which will be the first-ever cross-brand retail experience for IKEA U.S., aims to "make it easier to integrate Best Buy appliances into IKEA kitchens and home laundry areas." Here's what to know about the IKEA and Best Buy mashup, including where the service will be available. Why are IKEA and Best Buy joining forces? According to Rob Olson, the chief operations officer for IKEA U.S., the partnership will create what he called a "one-stop destination where customers can design their dream kitchen, storage solutions or laundry space with ease." The new in-store collaboration between the retailers will initially launch in 10 stores throughout Florida and Texas, and feature 1,000-square-foot IKEA footprints that "showcase inspirational kitchen and laundry room settings," according to the release. At these stores, customers can receive support from IKEA workers to plan and order home furnishing products, as well as get advice on electronics from Best Buy employees. Where will the Best Buy and IKEA pilot locations be? Here are the 10 Best Buy stores that will feature an IKEA shop-in-shop later this year: Additionally, two stores – Lakeland, Florida, and Alamo Ranch, Texas – will serve as pick-up points for IKEA shoppers. Customers in these markets will be able to pick up most IKEA U.S. products for free at these Best Buy stores, regardless of whether they were purchased through the new IKEA in Best Buy design experience or Jonathan Limehouse covers breaking and trending news for USA TODAY. Reach him at JLimehouse@
Business Upturn
2 hours ago
- Business Upturn
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor 'What This Means' Segment
By GlobeNewswire Published on July 31, 2025, 22:50 IST Access the 'What This Means' segment here LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) ('GRI Bio' or the 'Company'), a biotechnology company advancing an innovative pipeline of Natural Killer T ('NKT') cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor 'What This Means' segment. For the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discussed the Company's recently announced 6-week interim biomarker data from its ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis ('IPF'). The 'What This Means' segment can be accessed here. About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of Natural Killer T ('NKT') cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT ('iNKT') cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT ('dNKT') agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775 [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
